Angiotensin-Neprilysin Inhibition in Diastolic Dysfunction After AMI

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

51 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-10-12

Study Completion Date

2023-06-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study examines the effect of Entresto on central hemodynamic parameters during exercise in patients with diastolic dysfunction following acute myocardial infarction. Half of the patients will receive Entresto and the other half will receive placebo.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Angiotensin Receptor Blockers in Aortic Stenosis

NCT04913870

Aortic Stenosis Aortic Valve Stenosis

RECRUITING PHASE4

Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction

NCT03506412

Heart Failure With Preserved Ejection Fraction

COMPLETED PHASE4

European Trial of Dronedarone in Moderate to Severe Congestive Heart Failure

NCT00696631

Congestive Heart Failure

TERMINATED PHASE3

Beginning a Randomized Evaluation of the AGE Breaker Alagebrium in Diastolic Heart Failure (BREAK-DHF-I)

NCT00662116

Diastolic Heart Failure

TERMINATED PHASE2

Evaluation of Enalapril Versus Placebo in Patients With Diastolic Heart Failure

NCT01411735

Heart Failure With Preserved Ejection Fraction Heart Failure, Congestive

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In patients with acute myocardial infraction (AMI) only 25-33% have entirely normal left ventricular (LV) systolic and diastolic function. Studies have show that echocardiographic signs of increased LV filling pressure (diastolic dysfunction) are associated with poor outcome after AMI. The optimal management of this group of patients is currently not known. LCZ696 is a novel combination drug consisting of two antihypertensives, sacubitril and valsartan. LCZ696 have demonstrated to reduce mortality in patients with systolic heart failure. In patients with heart failure with preserved ejection fraction a positive effect has been demonstrated on natriuretic peptides and left atrial remodelling when treated with LCZ696, further, experimental data suggest inhibition of cardiac fibrosis.

Hypothesis:

LCZ696 compared with placebo will improve central hemodynamics (reduce pulmonary capillary wedge pressure (PCWP)), and increase cardiac index (CI) during exercise in patients with diastolic dysfunction following AMI. A beneficial effect that is attributed to improved cardiac remodelling (attenuation of cardiac fibrosis).

Primary objective To asses the effect of 6 months treatment with LCZ696 compared with placebo on ratio of PCWP/CI during exercise in patients with a recent AMI and Doppler echocardiographic signs of diastolic dysfunction and preserved systolic function.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myocardial Infarction Diastolic Dysfunction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Entresto

Combination of valsartan and sacubitril titrated to 103+97 mg B.I.D. for 26 weeks

Group Type ACTIVE_COMPARATOR

Entresto Pill

Intervention Type DRUG

NO other interventions

Placebo

Matching placebo B.I.D. for 26 weeks

Group Type PLACEBO_COMPARATOR

Entresto Pill

Intervention Type DRUG

NO other interventions

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Entresto Pill

NO other interventions

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Valsartan+ sacubitril

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Documented ST segment elevation or non ST- myocardial infarction according to current guidelines
2. Complete revascularization
3. Age ≥50 years
4. LVEF ≥45% on echocardiography performed within 72 hours of the MI.
5. Diastolic dysfunction defined as: Ratio of early diastolic peak mitral inflow velocity (E) to early mitral annulus diastolic velocity (e') ratio \> 8 and at least moderate LA dilatation (LA volume index\>34 mL/m2).
6. Signed informed consent

Exclusion Criteria

1. Intolerance towards study medication
2. Permanent atrial fibrillation,
3. Known history of cardiomyopathy,
4. More than mild valvular heart disease,
5. Severe obstructive or restrictive pulmonary disease,
6. Inability to perform exercise testing,
7. Inadequate acoustic windows on echocardiography,
8. Ongoing treatment with an angiotensin converting enzyme inhibitor at randomization.
9. Class I indication for an angiotensin converting enzyme inhibitor
10. Symptomatic hypotension, a systolic blood pressure of less than 100 mm Hg at screening
11. An estimated glomerular filtration rate (eGFR) below 30 ml per minute per 1.73 m2 of body-surface area at any time,
12. A serum potassium level of more than 5.2 mmol per liter at screening,
13. A history of hereditary or idiopathic angioedema or unacceptable side effects during receipt of angiotensin converting enzyme inhibitor or angiotensin receptor blocker
14. Inability to provide informed consent
15. Concomitant use of drugs containing aliskiren in patients with diabetes mellitus.
16. Severe reduced liver function, biliary cirrhosis or cholestasis (Child-Pugh class C)
17. Pregnant or nursing(lactating) women(see section 8.2.1 for details)
18. Fertile women unless they are using a highly effective method of contraception(see section 8.2.2 for details)

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No